Tirdzniecība Bristol-Myers Squibb Co - BMY CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Tirdzniecības Nosacījumi
| Starpība | 0.19 | ||||||||
|
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.030779% | ||||||||
|
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | -0.013666% | ||||||||
| Nakts laika nodeva | 22:00 (UTC) | ||||||||
| Min. tirgotais daudzums | 1 | ||||||||
| Valūta | USD | ||||||||
| Drošības rezerve | 20% | ||||||||
| Fondu birža | United States of America | ||||||||
| Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Bristol-Myers Squibb Co ESG Risk Ratings
High Medium Low Negligible
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Galvenie Statistikas Dati
| Iepriekš. aizvērt* | 72.58 |
| Atvērt* | 72.48 |
| Izmaiņas par 1 gadu* | 11.8% |
| Dienas Diapazons* | 70.77 - 72.62 |
| 52 ned Diapazons | 62.90-81.44 |
| Vidējais apjoms (10 dienas) | 7.99M |
| Vidējais apjoms (3 mēneši) | 180.84M |
| Tirgus Kapitalizācija | 154.47B |
| Cenas/Peļņas Attiecība | 23.68 |
| Izvietotās Akcijas | 2.13B |
| Ieņēmumi | 46.74B |
| EPS | 3.07 |
| Dividende (Ienesīgums %) | 3.13833 |
| Beta | 0.42 |
| Nākamās Peļņas Datums | Feb 2, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
|---|---|---|---|---|---|---|
| Feb 1, 2023 | 71.10 | -1.20 | -1.66% | 72.30 | 72.76 | 69.93 |
| Jan 31, 2023 | 72.58 | 0.95 | 1.33% | 71.63 | 72.58 | 71.56 |
| Jan 30, 2023 | 71.96 | -0.32 | -0.44% | 72.28 | 72.82 | 71.77 |
| Jan 27, 2023 | 72.37 | -0.20 | -0.28% | 72.57 | 73.37 | 72.19 |
| Jan 26, 2023 | 72.90 | 0.30 | 0.41% | 72.60 | 73.11 | 71.83 |
| Jan 25, 2023 | 73.07 | 0.68 | 0.94% | 72.39 | 73.16 | 71.79 |
| Jan 24, 2023 | 72.28 | -0.48 | -0.66% | 72.76 | 73.38 | 71.93 |
| Jan 23, 2023 | 73.15 | -0.78 | -1.06% | 73.93 | 74.11 | 72.73 |
| Jan 20, 2023 | 74.07 | 0.30 | 0.41% | 73.77 | 74.07 | 73.22 |
| Jan 19, 2023 | 73.67 | 2.24 | 3.14% | 71.43 | 73.79 | 71.43 |
| Jan 18, 2023 | 72.07 | 0.11 | 0.15% | 71.96 | 72.59 | 71.07 |
| Jan 17, 2023 | 72.23 | -0.67 | -0.92% | 72.90 | 73.38 | 71.91 |
| Jan 13, 2023 | 72.42 | 0.92 | 1.29% | 71.50 | 72.44 | 71.23 |
| Jan 12, 2023 | 71.53 | 0.08 | 0.11% | 71.45 | 71.86 | 70.93 |
| Jan 11, 2023 | 71.85 | 0.38 | 0.53% | 71.47 | 71.90 | 70.79 |
| Jan 10, 2023 | 71.58 | 0.44 | 0.62% | 71.14 | 71.62 | 70.57 |
| Jan 9, 2023 | 70.94 | -1.77 | -2.43% | 72.71 | 72.96 | 70.68 |
| Jan 6, 2023 | 72.94 | 1.33 | 1.86% | 71.61 | 73.32 | 71.61 |
| Jan 5, 2023 | 71.83 | 0.14 | 0.20% | 71.69 | 72.31 | 71.37 |
| Jan 4, 2023 | 72.53 | 0.46 | 0.64% | 72.07 | 73.18 | 71.45 |
Bristol-Myers Squibb Co Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Ikgadējs
- Ceturkšņa
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Kopējie ienākumi | 19427 | 20776 | 22561 | 26145 | 42518 | 46385 |
| Ienākumi | 19427 | 20776 | 22561 | 26145 | 42518 | 46385 |
| Cost of Revenue, Total | 4925 | 5917 | 6436 | 7804 | 11133 | 9601 |
| Bruto Peļņa | 14502 | 14859 | 16125 | 18341 | 31385 | 36784 |
| Kopējie Darbības Izdevumi | 13480 | 15532 | 16175 | 19758 | 49365 | 37770 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 4911 | 4687 | 4550 | 4870 | 7733 | 7688 |
| Pētniecība un Attīstība | 4927 | 4823 | 5052 | 5845 | 9519 | 9532 |
| Depreciation / Amortization | 21 | 3 | 41 | 1206 | 9688 | 10023 |
| Neparedzēti Izdevumi (Ienākumi) | -585 | 1453 | 1449 | 1393 | 12819 | 2659 |
| Other Operating Expenses, Total | -719 | -1351 | -1353 | -1360 | -1527 | -1733 |
| Darbības Izdevumi | 5947 | 5244 | 6386 | 6387 | -6847 | 8615 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | 15 | 33 | -380 | -69 | -71 | -550 |
| Citi, Neto | -47 | -146 | -38 | -1343 | 47 | 33 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | 5915 | 5131 | 5968 | 4975 | -6871 | 8098 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | 4507 | 3871 | 5003 | 3460 | -8995 | 7014 |
| Mazākuma Interese | -50 | 32 | -27 | -21 | -20 | -20 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | 4457 | 3903 | 4976 | 3439 | -9015 | 6994 |
| Neto Ienākumi | 4457 | 1007 | 4920 | 3439 | -9015 | 6994 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | 4457 | 3903 | 4976 | 3439 | -9015 | 6994 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | 4457 | 1007 | 4920 | 3439 | -9015 | 6994 |
| Atšķaidītie Neto Ienākumi | 4457 | 1007 | 4920 | 3439 | -9015 | 6994 |
| Atšķaidītie Ienākumi par Akcijām | 1680 | 1652 | 1637 | 1712 | 2258 | 2245 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | 2.65298 | 2.36259 | 3.03971 | 2.00876 | -3.99247 | 3.11537 |
| Dividends per Share - Common Stock Primary Issue | 1.52 | 1.56 | 1.6 | 1.64 | 1.8 | 1.96 |
| Atšķaidītā Normalizētā Peļņa par Akciju | 2.38949 | 3.03729 | 3.78174 | 2.58034 | -0.19982 | 3.81069 |
| Ārkārtas Posteņi Kopā | -2896 | -56 | 0 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 11073 | 11703 | 11624 | 11985 | 11648 |
| Ienākumi | 11073 | 11703 | 11624 | 11985 | 11648 |
| Cost of Revenue, Total | 2503 | 2451 | 2291 | 2356 | 2471 |
| Bruto Peļņa | 8570 | 9252 | 9333 | 9629 | 9177 |
| Kopējie Darbības Izdevumi | 8812 | 9988 | 9628 | 9342 | 9095 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 1667 | 1882 | 1787 | 2352 | 1829 |
| Pētniecība un Attīstība | 2225 | 2261 | 2440 | 2607 | 2220 |
| Depreciation / Amortization | 2513 | 2547 | 2546 | 2417 | 2417 |
| Neparedzēti Izdevumi (Ienākumi) | 271 | 1252 | 989 | 146 | 635 |
| Other Operating Expenses, Total | -367 | -405 | -425 | -536 | -477 |
| Darbības Izdevumi | 2261 | 1715 | 1996 | 2643 | 2553 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | 257 | -170 | 149 | -786 | -960 |
| Citi, Neto | 12 | 8 | 12 | 1 | 94 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | 2530 | 1553 | 2157 | 1858 | 1687 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | 2029 | 1061 | 1552 | 2372 | 1283 |
| Mazākuma Interese | -8 | -6 | -6 | 0 | -5 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | 2021 | 1055 | 1546 | 2372 | 1278 |
| Neto Ienākumi | 2021 | 1055 | 1546 | 2372 | 1278 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | 2021 | 1055 | 1546 | 2372 | 1278 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | 2021 | 1055 | 1546 | 2372 | 1278 |
| Atšķaidītie Neto Ienākumi | 2021 | 1055 | 1546 | 2372 | 1278 |
| Atšķaidītie Ienākumi par Akcijām | 2265 | 2252 | 2243 | 2221 | 2164 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | 0.89227 | 0.46847 | 0.68926 | 1.06799 | 0.59057 |
| Dividends per Share - Common Stock Primary Issue | 0.49 | 0.49 | 0.49 | 0.49 | 0.54 |
| Atšķaidītā Normalizētā Peļņa par Akciju | 0.89007 | 0.85213 | 1.0486 | 1.02071 | 0.81817 |
- Ikgadējs
- Ceturkšņa
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 13704 | 14854 | 17160 | 29354 | 30192 | 33262 |
| Nauda un Īstermiņa Ieguldījumi | 6350 | 6812 | 8884 | 15393 | 15831 | 16966 |
| Nauda un Ekvivalenti | 4237 | 5421 | 6911 | 12346 | 14546 | 13979 |
| Īstermiņa Ieguldījumi | 2113 | 1391 | 1973 | 3047 | 1285 | 2987 |
| Debitoru Parādu Kopsumma, Neto | 4916 | 5609 | 5747 | 7685 | 8501 | 9369 |
| Accounts Receivable - Trade, Net | 3774 | 4347 | 4636 | 6476 | 7219 | 7979 |
| Total Inventory | 1241 | 1166 | 1195 | 4293 | 2074 | 2095 |
| Prepaid Expenses | 627 | 691 | 218 | 754 | 1799 | 2786 |
| Other Current Assets, Total | 570 | 576 | 1116 | 1229 | 1987 | 2046 |
| Total Assets | 33707 | 33551 | 34986 | 129944 | 118481 | 109314 |
| Property/Plant/Equipment, Total - Net | 4980 | 5001 | 5027 | 6956 | 6745 | 6968 |
| Property/Plant/Equipment, Total - Gross | 9173 | 8987 | 8845 | 10911 | 10330 | 11001 |
| Accumulated Depreciation, Total | -4193 | -3986 | -3818 | -3955 | -3585 | -4033 |
| Goodwill, Net | 6875 | 6863 | 6538 | 22488 | 20547 | 20502 |
| Intangibles, Net | 1385 | 1210 | 1091 | 63969 | 53243 | 42527 |
| Long Term Investments | 2719 | 2480 | 1775 | 4601 | 4509 | 2713 |
| Other Long Term Assets, Total | 4044 | 3143 | 3395 | 2576 | 3245 | 3342 |
| Total Current Liabilities | 8841 | 9563 | 10654 | 18304 | 19080 | 21868 |
| Accounts Payable | 1664 | 2248 | 1892 | 2445 | 2713 | 2949 |
| Accrued Expenses | 4587 | 5313 | 5687 | 8100 | 9582 | 10104 |
| Notes Payable/Short Term Debt | 243 | 987 | 454 | 583 | 340 | 184 |
| Current Port. of LT Debt/Capital Leases | 749 | 0 | 1249 | 2763 | 2000 | 4764 |
| Other Current Liabilities, Total | 1598 | 1015 | 1372 | 4413 | 4445 | 3867 |
| Total Liabilities | 17530 | 21810 | 20955 | 78346 | 80659 | 73368 |
| Total Long Term Debt | 5716 | 6975 | 5646 | 43387 | 48336 | 39605 |
| Long Term Debt | 5716 | 6975 | 5646 | 43387 | 48336 | 39605 |
| Minority Interest | 170 | 106 | 96 | 100 | 60 | 60 |
| Other Liabilities, Total | 2803 | 5166 | 4559 | 10101 | 7776 | 7334 |
| Total Equity | 16177 | 11741 | 14031 | 51598 | 37822 | 35946 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 221 | 221 | 221 | 292 | 292 | 292 |
| Additional Paid-In Capital | 1725 | 1898 | 2081 | 43709 | 44325 | 44361 |
| Retained Earnings (Accumulated Deficit) | 33513 | 31160 | 34065 | 34474 | 21281 | 23820 |
| Treasury Stock - Common | -16779 | -19249 | -19574 | -25357 | -26237 | -31259 |
| Unrealized Gain (Loss) | -7 | 32 | -30 | 6 | 11 | 2 |
| Other Equity, Total | -2496 | -2321 | -2732 | -1526 | -1850 | -1270 |
| Total Liabilities & Shareholders’ Equity | 33707 | 33551 | 34986 | 129944 | 118481 | 109314 |
| Total Common Shares Outstanding | 1664 | 1625 | 1624 | 2228 | 2221 | 2153 |
| Total Preferred Shares Outstanding | 0.00413 | 0.00407 | ||||
| Deferred Income Tax | 6454 | 5407 | 4501 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 27111 | 29161 | 31443 | 33262 | 30121 |
| Nauda un Īstermiņa Ieguldījumi | 12930 | 14016 | 15823 | 16966 | 14968 |
| Nauda un Ekvivalenti | 10982 | 11024 | 13540 | 13979 | 12369 |
| Īstermiņa Ieguldījumi | 1948 | 2992 | 2283 | 2987 | 2599 |
| Debitoru Parādu Kopsumma, Neto | 8660 | 11275 | 11738 | 9369 | 8511 |
| Accounts Receivable - Trade, Net | 7187 | 7713 | 7878 | 7979 | 7156 |
| Total Inventory | 1953 | 2137 | 2163 | 2095 | 2104 |
| Other Current Assets, Total | 3568 | 1733 | 1719 | 2046 | 4538 |
| Total Assets | 112435 | 110797 | 110893 | 109314 | 103034 |
| Property/Plant/Equipment, Total - Net | 6613 | 6801 | 6835 | 6968 | 6941 |
| Property/Plant/Equipment, Total - Gross | 10243 | 10639 | 10805 | 11001 | 11109 |
| Accumulated Depreciation, Total | -3630 | -3838 | -3970 | -4033 | -4168 |
| Goodwill, Net | 20524 | 20529 | 20519 | 20502 | 20500 |
| Intangibles, Net | 50819 | 48065 | 44930 | 42527 | 40103 |
| Long Term Investments | 4636 | 3765 | 4784 | 2713 | 2185 |
| Other Long Term Assets, Total | 2732 | 2476 | 2382 | 3342 | 3184 |
| Total Current Liabilities | 17330 | 18991 | 21460 | 21868 | 22821 |
| Accounts Payable | 2972 | 3609 | 2695 | 2949 | 2944 |
| Accrued Expenses | 8491 | 8962 | 9971 | 10104 | 8319 |
| Notes Payable/Short Term Debt | 277 | 158 | 296 | 184 | 225 |
| Current Port. of LT Debt/Capital Leases | 1500 | 2497 | 4769 | 4764 | 7297 |
| Other Current Liabilities, Total | 4090 | 3765 | 3729 | 3867 | 4036 |
| Total Liabilities | 74830 | 73989 | 73680 | 73368 | 71454 |
| Total Long Term Debt | 44505 | 42503 | 39677 | 39605 | 37450 |
| Long Term Debt | 44505 | 42503 | 39677 | 39605 | 37450 |
| Deferred Income Tax | 5235 | 4931 | 4956 | 4501 | 3809 |
| Minority Interest | 68 | 66 | 71 | 60 | 65 |
| Other Liabilities, Total | 7692 | 7498 | 7516 | 7334 | 7309 |
| Total Equity | 37605 | 36808 | 37213 | 35946 | 31580 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 292 | 292 | 292 | 292 | 292 |
| Additional Paid-In Capital | 43852 | 44064 | 44292 | 44361 | 43756 |
| Retained Earnings (Accumulated Deficit) | 22204 | 22168 | 22625 | 23820 | 23948 |
| Treasury Stock - Common | -27199 | -28198 | -28572 | -31259 | -35187 |
| Unrealized Gain (Loss) | 9 | 7 | 4 | 2 | 1 |
| Other Equity, Total | -1553 | -1525 | -1428 | -1270 | -1230 |
| Total Liabilities & Shareholders’ Equity | 112435 | 110797 | 110893 | 109314 | 103034 |
| Total Common Shares Outstanding | 2232.84 | 2222.11 | 2219.65 | 2153 | 2129.06 |
| Prepaid Expenses | 2786 |
- Ikgadējs
- Ceturkšņa
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Neto ienākumi/Sākuma Līnija | 4507 | 975 | 4947 | 3460 | -8995 | 7014 |
| Nauda no Darbības | 3058 | 5275 | 5940 | 8067 | 14052 | 16207 |
| Nauda no Darbības | 382 | 789 | 637 | 1746 | 10380 | 10686 |
| Deferred Taxes | -204 | 1010 | 86 | -924 | 983 | -1393 |
| Bezskaidras Naudas Preces | -475 | 913 | 94 | 720 | 10701 | 1153 |
| Cash Taxes Paid | 2000 | 546 | 747 | 1503 | 3400 | 3500 |
| Samaksātie Procenti Naudā | 191 | 215 | 212 | 414 | 1600 | 1500 |
| Izmaiņas Apgrozāmajā Kapitālā | -1152 | 1588 | 176 | 3065 | 983 | -1253 |
| Nauda no Ieguldījumu Darbībām | 1480 | -66 | -874 | -9770 | -10859 | -538 |
| Kapitālie Izdevumi | -1215 | -1055 | -951 | -836 | -753 | -973 |
| Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | 2695 | 989 | 77 | -8934 | -10106 | 435 |
| Nauda no Darbībām ar Finansēšanu | -2653 | -4077 | -3535 | 7621 | -1151 | -16224 |
| Naudas Plūsma Finansēšanas Posteņos | 15 | -22 | -54 | -53 | 542 | 641 |
| Total Cash Dividends Paid | -2547 | -2577 | -2613 | -2679 | -4075 | -4396 |
| Akciju Izsniegšana (Atkāpšanās), Neto | -231 | -2469 | -320 | -7300 | -1546 | -6287 |
| Parādu Izsniegšana (Atkāpšanās), Neto | 110 | 991 | -548 | 17653 | 3928 | -6182 |
| Ārvalstu Valūtas Ietekme | -33 | 52 | -41 | -9 | 111 | -102 |
| Neto Izmaiņas Naudā | 1852 | 1184 | 1490 | 5909 | 2153 | -657 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 2029 | 3090 | 4642 | 7014 | 1283 |
| Cash From Operating Activities | 3824 | 6884 | 12150 | 16207 | 3812 |
| Cash From Operating Activities | 2668 | 5380 | 8107 | 10686 | 2584 |
| Deferred Taxes | 68 | -95 | -127 | -1393 | -687 |
| Non-Cash Items | -507 | 356 | 725 | 1153 | 994 |
| Changes in Working Capital | -434 | -1847 | -1197 | -1253 | -362 |
| Cash From Investing Activities | -143 | 37 | -939 | -538 | 95 |
| Capital Expenditures | -173 | -383 | -653 | -973 | -253 |
| Other Investing Cash Flow Items, Total | 30 | 420 | -286 | 435 | 348 |
| Cash From Financing Activities | -7295 | -10477 | -12257 | -16224 | -5653 |
| Financing Cash Flow Items | 172 | 448 | 644 | 641 | 333 |
| Total Cash Dividends Paid | -1108 | -2207 | -3297 | -4396 | -1185 |
| Issuance (Retirement) of Stock, Net | -1775 | -3011 | -3536 | -6287 | -5000 |
| Issuance (Retirement) of Debt, Net | -4584 | -5707 | -6068 | -6182 | 199 |
| Foreign Exchange Effects | -38 | -20 | -48 | -102 | 9 |
| Net Change in Cash | -3652 | -3576 | -1094 | -657 | -1737 |
| Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
|---|---|---|---|---|---|---|
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.3545 | 198890804 | 3066015 | 2022-09-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.2989 | 112662905 | 2240471 | 2022-09-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.3424 | 92325898 | -602471 | 2022-09-30 | LOW |
| JP Morgan Asset Management | Investment Advisor | 3.0052 | 63894939 | 526421 | 2022-09-30 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 2.9555 | 62838772 | -1753198 | 2022-09-30 | LOW |
| Capital International Investors | Investment Advisor | 2.4644 | 52396432 | 14298520 | 2022-09-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.8412 | 39147135 | 1131303 | 2022-09-30 | LOW |
| Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 1.5702 | 33385956 | -2374239 | 2022-09-30 | LOW |
| BofA Global Research (US) | Research Firm | 1.0777 | 22914303 | 1075724 | 2022-09-30 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.0666 | 22677818 | -372517 | 2021-12-31 | LOW |
| Managed Account Advisors LLC | Investment Advisor | 1.0476 | 22273448 | -2068389 | 2022-09-30 | LOW |
| PRIMECAP Management Company | Investment Advisor | 1.0412 | 22137675 | -74030 | 2022-09-30 | LOW |
| Columbia Threadneedle Investments (US) | Investment Advisor/Hedge Fund | 0.9424 | 20037642 | -147066 | 2022-09-30 | LOW |
| Dodge & Cox | Investment Advisor/Hedge Fund | 0.789 | 16775562 | -1577777 | 2022-09-30 | LOW |
| Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.7761 | 16501572 | -551586 | 2022-09-30 | LOW |
| Nuveen LLC | Pension Fund | 0.7673 | 16313175 | 698391 | 2022-09-30 | LOW |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7056 | 15001848 | -146955 | 2022-09-30 | LOW |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.6895 | 14659982 | 155845 | 2022-09-30 | LOW |
| BlackRock Asset Management Ireland Limited | Investment Advisor | 0.6759 | 14370082 | -23245 | 2022-09-30 | LOW |
| Morgan Stanley Smith Barney LLC | Investment Advisor | 0.6643 | 14124064 | -3100460 | 2022-09-30 | LOW |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com Group +485000+
Tirgotāji
65000+
Ikmēneša aktīvie klienti
$48000000+
Ikmēneša ieguldījumu apjoms
$28000000+
Izmēģināt tagad Izņemts katru mēnesi
Treidinga kalkulators
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Tirdzniecības komisija
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Finanšu svira
20:1
- 20
- 100
- 500
- 1000
- 10000
Investīcija
Darījuma apjoms (Kredītplecs x Investīcija):
Atvēršana
Aizvēršana
Īss Garšs
Bristol-Myers Squibb Company profile
Par Bristol-Myers Squibb Co
Bristol-Myers Squibb Company ir biofarmācijas uzņēmums. Uzņēmums nodarbojas ar biofarmaceitisko produktu atklāšanu, izstrādi, licencēšanu, ražošanu, mārketingu, izplatīšanu un pārdošanu. Uzņēmums piedāvā produktus dažādām terapeitiskajām grupām, tostarp onkoloģijai, imunoloģijai, sirds un asinsvadu slimībām un fibrozei. Sabiedrības farmācijas produkti ietver ķīmiski sintezētas jeb mazmolekulāras zāles un produktus, kas ražoti bioloģiskos procesos, tā sauktos bioloģiskos produktus. Mazmolekulārās zāles tiek lietotas iekšķīgi tablešu vai tablešu veidā. Bioloģiskās zāles pacientiem tiek ievadītas injekciju vai infūzijas veidā. Uzņēmuma produkti ir Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude un Breyanzi. Uzņēmuma produkti tiek pārdoti vairumtirgotājiem, izplatītājiem, aptiekām, mazumtirgotājiem, slimnīcām, klīnikām un valsts iestādēm.
| Industry: | Pharmaceuticals (NEC) |
430 E. 29Th Street
14 Floor
NEW YORK
NEW YORK 10016
US
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 485 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com